Despite concerns about safety signals and data packages that made effectiveness in the most vulnerable elders difficult to evaluate, the FDA’s vaccines advisory committee this week endorsed the safety and effectiveness of two vaccines against respiratory syncytial virus (RSV), a common and dangerous respiratory pathogen that currently has no effective treatments. The committee’s concerns show how the shadow of pandemic-related vaccine hesitancy continues to dog these discussions.
Fill out the form to read the full article.
